Guardant Health (GH) Cash & Equivalents (2017 - 2026)

Guardant Health (GH) has 10 years of Cash & Equivalents data on file, last reported at $989.3 million in Q1 2026.

• Quarterly Cash & Equivalents rose 41.62% year-over-year to $989.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $989.3 million (up 41.62% YoY) and the FY2025 annual result came in at $378.2 million, down 28.04% from the prior year.
• Cash & Equivalents rose to $989.3 million in Q1 2026 per GH's latest filing, from $378.2 million in the prior quarter.
• The five-year high for Cash & Equivalents was $1.1 billion in Q4 2023, with the low at $141.6 million in Q4 2022.
• Average Cash & Equivalents over 5 years is $560.2 million, with a median of $573.6 million recorded in 2022.
• Year-over-year, Cash & Equivalents plunged 80.98% in 2022 and soared 700.25% in 2023.
• Guardant Health's Cash & Equivalents stood at $141.6 million in 2022, then jumped by 700.25% to $1.1 billion in 2023, then sank by 53.64% to $525.5 million in 2024, then fell by 28.04% to $378.2 million in 2025, then jumped by 161.58% to $989.3 million in 2026.
• Business Quant data shows GH's Cash & Equivalents at $989.3 million in Q1 2026, $378.2 million in Q4 2025, and $580.0 million in Q3 2025.